Development of novel interventions, including therapeutics and devices, to prevent cardiovascular disease and stroke; develop novel treatments and devices to improve outcomes; and conduct small-scale development projects to establish feasible, evidence-based approaches aimed at improving survivorship and reducing morbidity.
To find out more, register for the HTSA MRFF Catalyst Grant Scheme Launch Webinar Wednesday May 10th, 12pm-1pm ACST
Applications will be open from 1 July 2021 at 9 am ACST and be closed at 30 July 2021 at 4 pm ACST.
Photo by Nathan Anderson on Unsplash.
Minimum Data closes at 5:00 pm (ACT Local Time) on 22 June 2022
Minimum Data closes at 5:00 pm (ACT Local Time) on 23 February 2022
Minimum Data closes at 5:00 pm (ACT Local Time) on 20 April 2022
Minimum Data closes at 5:00 pm (ACT Local Time) on 29 June 2022
Minimum Data closes at 5:00 pm (ACT Local Time) on 29 June 2022
Minimum Data closes at 5:00 pm (ACT Local Time) on 29 June 2022
Minimum Data closes at 5:00 pm (ACT Local Time) on 29 June 2022
Minimum Data closes at 5:00 pm (ACT Local Time) on 29 June 2022
Minimum Data closes at 5:00 pm (ACT Local Time) on 16 February 2022
Minimum Data closes at 5:00 pm (ACT Local Time) on 9 Feb 2022
Minimum Data closes at 5:00 pm (ACT Local Time) on Wednesday 02 February 2022.
Minimum Data closes at 5:00 pm (ACT Local Time) on Wednesday 2 February 2022.
Minimum data due 1700 ACT local time, 24 November 2021.
Minimum Data closes at 5:00 pm (ACT Local Time) on 9 February 2022.
Minimum Data closes at 5:00 pm (ACT Local Time) on 9 February 2022.
Minimum Data closes at 5:00 pm (ACT Local Time) on 25 Jan 2022.
An information session will be held on Tuesday 12 October, registration can be made here.
Minimum Data closes at 5:00 pm (ACT Local Time) on 16 February 2022.
Minimum Data closes at 5:00 pm (ACT Local Time) on 2 February 2022.
Minimum Data Dates:
Round 1: 5pm ACT local time on 25 August 2021
Round 2: 5pm ACT local time on 2 February 2022
Expressions of interest close 19 April 2021.
Minimum Data: 5pm ACT local time on 7 July 2021
Expressions of interest are open and will need to be submitted by 17th December 2021 by 5pm by email to hcffoundation@hcf.com.au
Expressions of interest close 10 March 2021
Strategic investment in data registries, biobanks and data linkage platforms for primary health care in a range of settings.
Projects should aim to improve medicine use and medicine intervention by pharmacists in primary health and transitions of care.
Clinical trial in Australia, in collaboration with international counterparts.
Stream 1: utilise existing evidence to develop or improve approaches for the early diagnosis of ovarian cancer, cancers of the pancreas, liver cancer or lung cancer that have a clinically feasible pathway to implementation
Stream 2: enable approaches for the early diagnosis of cancers with unknown primary site that have a clinically feasible pathway to implementation.
$17.5 million across 4 streams.
